Acumen Pharmaceuticals (ABOS) vs Seer (SEER)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Seer (SEER) has outperformed Acumen Pharmaceuticals (ABOS) over the past year, losing 6.0% versus a loss of 16.7%. Over five years, ABOS leads with a -88.2% price change compared with -93.9% for SEER. Acumen Pharmaceuticals is the larger company by market cap ($122.2 million vs $112.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABOS | SEER |
|---|---|---|
| Share price | $1.69 | $2.03 |
| Market cap | $122.22M | $112.41M |
| 1-day change | +1.20% | -0.49% |
| YTD return | -19.91% | +10.93% |
| 1-year return | -16.75% | -6.02% |
| 5-year return | -88.25% | -93.94% |
| EPS (TTM) | $-1.64 | $-1.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $16.58M |
| Revenue growth (YoY) | — | +16.99% |
| Net income (latest FY) | $-121.33M | $-73.60M |
| Gross margin | — | 51.06% |
| Operating margin | — | -470.45% |
| Net margin | — | -443.96% |
| 52-week high | $3.60 | $2.41 |
| 52-week low | $1.50 | $1.55 |
| Distance from 52-week high | -53.06% | -15.77% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +349.70% | +97.04% |
| Average volume | 439.26K | 469.41K |
| Shares outstanding | 72.32M | 55.37M |
| Employees | 60 | 124 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SEER has outperformed ABOS by 10.7 percentage points over the past year.
About Acumen Pharmaceuticals
ABOS stock →Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers.
Healthcare · Biotechnology · 60 employees
About Seer
SEER stock →Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.
Healthcare · Biotechnology · 124 employees
ABOS vs SEER FAQ
Which is bigger, Acumen Pharmaceuticals or Seer?
Acumen Pharmaceuticals (ABOS) is larger, with a market capitalization of $122.22M compared with $112.41M for Seer (SEER).
Which stock has performed better over the past year, ABOS or SEER?
SEER returned -6.02% over the past 12 months, compared with -16.75% for ABOS (price return, excluding dividends). Past performance does not predict future results.
Are Acumen Pharmaceuticals and Seer in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.